Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
Physiopathological Roles of p2x Receptors in the Central Nervous System.
Risk factors for rare diseases can be risky to define: PML and natalizumab.
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
SIRT1 deacetylates RORγt and enhances Th17 cell generation.
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
The Relative Importance of Baseline Pain, Fatigue, Sleep and Physical Activity: Predicting Change in Depression in Adults with Multiple Sclerosis.
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Determination and characterization of a cannabinoid receptor in rat brain.
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
Roche's MabThera approved for two vasculitis indications in UK
Santhera to discontinue sale of Catena® in Canada
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.
The correlation between symptomatic fatigue to definite measures of gait in people with multiple sclerosis.
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Mitochondrial approaches for neuroprotection.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.

Pages